Hemispherx Biopharma
NYSE: AIMPhiladelphia, US · Delaware corporation
Founders & leadership
TK
Thomas K EquelsExecutive
AP
Adam PascaleExecutive
DS
David StrayerExecutive
WS
Wayne SpringateExecutive
Board
SA
Stewart AppelrouthBoard director
WM
William MitchellBoard director
PW
Peter W RodinoBoard director
Reported raises · per SEC filings
Form D private placements$3.4M disclosed across 4 rounds · 2016–2024
▶$3.3MraisedFeb 2024 · 1 investors · BiotechnologyRule 506(b)
▶$3.3MraisedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stewart AppelrouthDirector
- Thomas EqualsExecutive Officer, Director
- Nancy BryanDirector
- Rob DickeyExecutive Officer
- Peter RodinoExecutive Officer
- William MitchellDirector
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Minimum investment
- $2.5M
- Sales commissions
- $130K
- Placement agents
- Ascendiant Capital Markets, LLC
- First sale
- Feb 2024
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$25.7KraisedApr 2018 · 3 investors · PharmaceuticalsRule 506(b)
▶$25.7KraisedApr 2018 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adam PascaleExecutive Officer
- Thomas K EquelsExecutive Officer, Director
- David StrayerExecutive Officer
- Peter W RodinoExecutive Officer
- Stewart AppelrouthDirector
- Wayne SpringateExecutive Officer
- William MitchellDirector
- Offering amount
- $25.7K
- Amount sold
- $25.7K
- Minimum investment
- $975
- Sales commissions
- $1.8K
- Placement agents
- Maxim Group LLC
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2KraisedFeb 2017 · 4 investors · PharmaceuticalsRule 506(b)
▶$18.2KraisedFeb 2017 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David StrayerExecutive Officer
- Adam PascaleExecutive Officer
- Stewart AppelrouthDirector
- Peter W RodinoExecutive Officer
- William MitchellDirector
- Wayne SpringateExecutive Officer
- Thomas K EquelsExecutive Officer, Director
- Offering amount
- $18.2K
- Amount sold
- $18.2K
- Minimum investment
- $4.5K
- Sales commissions
- $1.3K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$33.3KraisedSep 2016 · 3 investors · PharmaceuticalsRule 506(b)
▶$33.3KraisedSep 2016 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas K EquelsExecutive Officer, Director
- Adam PascaleExecutive Officer
- Stewart AppelrouthDirector
- William MitchellDirector
- David StrayerExecutive Officer
- Peter W RodinoDirector
- Wayne SpringateExecutive Officer
- Offering amount
- $33.3K
- Amount sold
- $33.3K
- Minimum investment
- $6.6K
- Sales commissions
- $2.3K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Hemispherx Biopharma raised?
- Hemispherx Biopharma has disclosed $3.4M raised across 4 rounds.
- Where is Hemispherx Biopharma headquartered?
- Hemispherx Biopharma is headquartered in Philadelphia, US.